ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "administrative databases"

  • Abstract Number: 032 • 2020 Pediatric Rheumatology Symposium

    The Impact of Psychiatric Diagnosis and Treatment on Medication Adherence in Youth with Systemic Lupus Erythematosus

    Joyce Chang1, Alaina Davis 2, Marisa Klein-Gitelman 3, Zuleyha Cidav 4, David Mandell 5 and Andrea Knight 6, 1Children's Hospital of Philadelphia, Philadelphia, 2Monroe Carell Jr. Children’s Hospital at Vanderbilt, Nashville, Tennessee, 3Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, 4University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, 5Perelman School of Medicine at the University of Pennsylvania, Philadelphia, 6SickKids Research Institute, Toronto, Canada

    Background/Purpose: Youth with systemic lupus erythematosus (SLE) experience significant health care burden and high rates of psychiatric disorders. Optimizing medication adherence is critical for preventing…
  • Abstract Number: 058 • 2020 Pediatric Rheumatology Symposium

    Kawasaki Disease in Ontario Children from 1995-2017: A Population-based Descriptive Analysis

    Cal Robinson 1, Rahul Chanchlani 1, Megan Schlorff 1, Francis Lao 1, Tapas Mondal 1, Catherine Demers 1, Elizabeth Darling 1, Sandeep Brar 2, Rulan Parekh 3, Hsien Seow 1, Eric Benchimol 4 and Michelle Batthish1, 1McMaster University, Hamilton, Canada, 2University of California, San Fransisco, 3University of Toronto, Toronto, Canada, 4University of Ottawa, Ottawa, Canada

    Background/Purpose: Kawasaki disease (KD) is a childhood vasculitis with rising global incidence and the most common cause of childhood acquired heart disease in the developed…
  • Abstract Number: 1349 • 2019 ACR/ARP Annual Meeting

    Earlier Biologic Initiation over Two Decades of Real World Observational Data from the RAPPORT Biologics Registry of Northern Alberta, Canada

    Britney Jones1, Bo Pan 1, Joanne Homik 2, Anthony Russell 2, Walter P. Maksymowych 3, Jill Hall 1 and Stephanie Keeling 1, 1University of Alberta, Edmonton, AB, Canada, 2University of Alberta, Edmonton, Canada, 3University of Alberta/CARE ARTHRITIS, Edmonton, AB, Canada

    Background/Purpose: Rheumatoid (RA) and psoriatic arthritis (PsA) are inflammatory arthritides associated with significant potential functional disability if not well controlled. We reviewed the baseline demographic…
  • Abstract Number: 1426 • 2019 ACR/ARP Annual Meeting

    Impact of TNF Inhibitor Cycling with Adalimumab and Etanercept vs Switching to Tofacitinib

    James Harnett1, Timothy Smith 1, John Woolcott 2, David Gruben 3 and Christopher Murray 2, 1Pfizer Inc, New York, NY, 2Pfizer Inc, Collegeville, PA, 3Pfizer Inc, Groton, CT

    Background/Purpose: Tofacitinib is an oral JAK inhibitor for the treatment of RA. It was approved for RA by the US FDA in Nov 2012. TNFi…
  • Abstract Number: 1164 • 2018 ACR/ARHP Annual Meeting

    Canadians’ Views about Using Big Data in Health Research from a National Online Survey: A Partnership of Patient-Consumers and Researchers

    Natalie McCormick1, Clayon Hamilton1,2, Cheryl L. Koehn3, Kelly English4, Allan Stordy5 and Linda Li1,6, 1Arthritis Research Canada, Richmond, BC, Canada, 2Physical Therapy, The University of British Columbia, Vancouver, BC, Canada, 3Arthritis Consumer Experts, Vancouver, BC, Canada, 4Arthritis Patient Advisory Board, Arthritis Research Canada, Richmond, BC, Canada, 5Canadian Skin Patient Alliance, Calgary, AB, Canada, 6Department of Physical Therapy, The University of British Columbia, Vancouver, BC, Canada

    Background/Purpose:                  Findings from health research using “big data” (large sets of routinely-collected healthcare data) have benefitted individual arthritis patients and society as-a-whole.  However, growing…
  • Abstract Number: 1754 • 2018 ACR/ARHP Annual Meeting

    Clinical and Economic Characteristics of Patients Diagnosed with Eosinophilic Granulomatosis with Polyangiitis (EGPA, formerly Churg-Strauss Syndrome) in the United States

    Christopher F Bell1, Matthew Lau1 and Qin Shen2, 1GlaxoSmithKline, Research Triangle Park, NC, 2GlaxoSmithKline, Collegeville, PA

    Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA), formerly Churg-Strauss Syndrome, is a rare, complex multisystem disorder belonging to a group of autoimmune inflammatory diseases characterized by…
  • Abstract Number: 1755 • 2018 ACR/ARHP Annual Meeting

    Burden of Illness Associated with Eosinophilic Granulomatosis with Polyangiitis (EGPA, formerly Churg-Strauss Syndrome): Evidence from a Managed Care Database in the United States

    Christopher F Bell1, Cori Blauer-Peterson2 and Jianbin Mao2, 1GlaxoSmithKline, Research Triangle Park, NC, 2Optum, Eden Prairie, MN

    Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA), is a rare, complex multisystem disorder, characterized by vascular inflammation and multisystem organ damage. EGPA manifests as asthma, rhinosinusitis,…
  • Abstract Number: 233 • 2018 ACR/ARHP Annual Meeting

    TNF Inhibitors: Prevalence of Use and Predictors of Treatment Non-Persistence in the 2011-2016 Medicare Population

    Nicholas S. Roetker, Yi Peng, Kimberly M. Nieman, Suying Li and David T. Gilbertson, Minneapolis Medical Research Foundation, Chronic Disease Research Group, Minneapolis, MN

    Background/Purpose: Use of tumor necrosis factor inhibitor (TNFi) drugs is common among patients with rheumatic disease who do not respond to conventional therapies. The aims…
  • Abstract Number: 278 • 2018 ACR/ARHP Annual Meeting

    The Effect of Patient, Prescriber and Region on the Initiation of First Biologic for Rheumatoid Arthritis: A Longitudinal Population Study

    Mark Tatangelo1, George A. Tomlinson2, Michael Paterson3, Nick Bansback4, Tara Gomes1, Alex Kopp3, Vandana Ahluwalia5 and Claire Bombardier6, 1University of Toronto, Toronto, ON, Canada, 2Medicine, Mount Sinai Hospital, Toronto, ON, Canada, 3Institute for Clinical Evaluative Sciences, Toronto, ON, Canada, 4St Paul's Hospital, Centre for Health Evaluation and Outcomes Sciences, Vancouver, BC, Canada, 5Ontario Rheumatology Association, Brampton, ON, Canada, 6Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada

    Background/Purpose: Prescribing the first biologic for rheumatoid arthritis is an important decision for physicians, payers, and patients with costs and clinical implications. Our aim was…
  • Abstract Number: 581 • 2018 ACR/ARHP Annual Meeting

    Comparative Analysis of Outcomes Among Patients with Rheumatoid Arthritis Initiating Tofacitinib in Combination with Oral MTX Who Discontinue, Interrupt, or Persist with MTX

    Stanley Cohen1, Boulos Haraoui2, Jeffrey R. Curtis3, Timothy Smith4, John Woolcott5, David Gruben6, Christopher W Murray5, Noriko Iikuni4, Andrew Koenig5 and James Harnett4, 1Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, 2Institut de Rhumatologie de Montreal, Montreal, QC, Canada, 3University of Alabama at Birmingham, Birmingham, AL, 4Pfizer Inc, New York, NY, 5Pfizer Inc, Collegeville, PA, 6Pfizer Inc, Groton, CT

    Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA, in combination with MTX or other non‑biologic (nb)DMARDs, or as monotherapy. Two…
  • Abstract Number: 199 • 2017 ACR/ARHP Annual Meeting

    Incremental Direct Medical Costs of Systemic Lupus Erythematosus Patients in the Years Preceding Diagnosis and the Impact of Sex: A General Population-Based Study

    Natalie McCormick1,2, Carlo Marra3 and J. Antonio Avina-Zubieta4, 1Arthritis Research Canada, Richmond, BC, Canada, 2Pharmaceutical Sciences, The University of British Columbia, Vancouver, BC, Canada, 3School of Pharmacy, University of Otago, Dunedin, New Zealand, 4Division of Rheumatology, Department of Medicine, University of British Columbia, Vancouver, BC, Canada

    Background/Purpose: Little is known about the healthcare costs of systemic lupus erythematosus (SLE) patients in the years leading up to SLE diagnosis.  We estimated the…
  • Abstract Number: 1000 • 2017 ACR/ARHP Annual Meeting

    Use of Mutual Information Theory in Development and Refinement of a Predictive Model for Early Identification of Ankylosing Spondylitis

    Atul A. Deodhar1, Cody Garges2, Oodaye Shukla2, Theresa Arndt2, Tara Grabowsky2 and Yujin Park3, 1Oregon Health & Science University, Portland, OR, 2HVH Precision Analytics, LLC, King of Prussia, PA, 3Novartis Pharmaceuticals Corporation, East Hanover, NJ

    Background/Purpose: Delayed diagnosis and treatment of ankylosing spondylitis (AS) contribute to the economic, physical and psychological burden on patients and their caregivers. The objective of…
  • Abstract Number: 1039 • 2017 ACR/ARHP Annual Meeting

    Influences for Therapeutic Changes in Rheumatoid Arthritis Patients from the Veterans Affairs Rheumatology Arthritis Registry Who Have Moderate to High Disease Activity

    Brian Sauer1, Jacob R. Stever1, Chia-Chen Teng, MS1, Neil Accortt2, David Collier2 and Grant Cannon1, 1Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, 2Amgen Inc., Thousand Oaks, CA

    Background/Purpose: Current guidelines encourage the measurement of rheumatoid arthritis (RA) disease activity to achieve a low disease state (treat-to-target). Many RA patients with documented moderate…
  • Abstract Number: 1054 • 2017 ACR/ARHP Annual Meeting

    Healthcare Utilization Profiles in Rheumatoid Arthritis – a Cluster Analysis

    Nina Mars1,2, Anne M Kerola2,3, Markku J Kauppi4,5, Matti Pirinen1, Outi Elonheimo6 and Tuulikki Sokka-Isler7, 1Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland, 2University of Helsinki, Helsinki, Finland, 3Department of Internal Medicine, Päijät-Häme Central Hospital, Lahti, Finland, 4School of Medicine, University of Tampere, Tampere, Finland, 5Department of Rheumatology, Päijät-Häme Central Hospital, Lahti, Finland, 6FCG Finnish Consulting Group Ltd., Helsinki, Finland, 7Rheumatology, Jyvaskyla Central Hospital, Jyvaskyla, Finland

    Background/Purpose: Utilization patterns in rheumatoid arthritis (RA) are complex. For targeted interventions, patients with special healthcare needs should be recognized. Our aim was to explore…
  • Abstract Number: 1525 • 2017 ACR/ARHP Annual Meeting

    Characteristics and Treatment Patterns Among Patients with Psoriatic Arthritis Initiating Subcutaneously Administered Biologics: Descriptive Analyses from a US Claims Database

    Kurt R. Oelke1, Rahul Garg2, Peter Hur3, Olivier Chambenoit3, Amar Q. Majjhoo4, Stephani Gray5, Kate Higgins5 and Jacqueline B. Palmer3, 1Rheumatic Disease Center, Glendale, WI, 2PRO Unlimited, Inc, East Hanover, NJ, 3Novartis Pharmaceuticals Corporation, East Hanover, NJ, 4Shores Rheumatology, St. Clair Shores, MI, 5Truven Health Analytics, Cambridge, MA

    Background/Purpose: To better understand the real-world efficacy of biologics for the treatment of psoriatic arthritis (PsA), there is a need to evaluate the persistence and…
  • 1
  • 2
  • 3
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology